GlassScriptPhysician profile
Adam O Mcdaniel
NPI 1497001184
$937.60
in general payments reported to CMS, 2019-2025
18 companies · $19.60 in 2025
The $19.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $60.82 · 2021: $141 · 2022: $213 · 2023: $175 · 2024: $159 · 2025: $19.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $178.18 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $156.14 | 2019-2024 | |
| Boston Scientific Corporation | $102.00 | 2022-2025 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $72.30 | 2022-2023 | |
| Nevro Corp. | $59.46 | 2022-2023 | Senza |
| Lilly USA, LLC | $59.12 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.22 | 2021-2024 | |
| Novo Nordisk INC | $46.30 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.26 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $36.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $31.89 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $20.32 | 2023 | Euflexxa |
| Phathom Pharmaceuticals, INC. | $17.73 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $14.20 | 2024 | Airsupra |
| Depuy Synthes Sales INC. | $13.84 | 2023 | Monovisc, Orthovisc |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $13.82 | 2023 | Zio Xt Patch |
| Assertio Therapeutics, INC. | $13.50 | 2019 | |
| Neurocrine Biosciences, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.